438 related articles for article (PubMed ID: 23324288)
1. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
[TBL] [Abstract][Full Text] [Related]
2. Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy.
Zhao M; Shi X; Liang J; Miao Y; Xie W; Zhang Y; Li X
Exp Eye Res; 2011 Dec; 93(6):921-6. PubMed ID: 22067127
[TBL] [Abstract][Full Text] [Related]
3. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
6. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
7. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
8. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
10. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
13. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production.
Park SW; Cho CS; Jun HO; Ryu NH; Kim JH; Yu YS; Kim JS; Kim JH
Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7718-26. PubMed ID: 23099493
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Delivery of VEGF-A
Mezu-Ndubuisi OJ; Wang Y; Schoephoerster J; Falero-Perez J; Zaitoun IS; Sheibani N; Gong S
Curr Eye Res; 2019 Mar; 44(3):275-286. PubMed ID: 30383455
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy.
Liu N; Chen L; Cai N
Int J Clin Exp Pathol; 2015; 8(5):4990-8. PubMed ID: 26191192
[TBL] [Abstract][Full Text] [Related]
20. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
